When Will Oral Tirzepatide Tablets Hit the Market?

The Race to Develop an Oral GIP/GLP-1 Agonist

Injectable tirzepatide, sold under the brand names Mounjaro and Zepbound, has reshaped the treatment of type 2 diabetes and obesity since its FDA approval in 2022. But for many patients, weekly self-injections remain a practical barrier to long-term adherence. Eli Lilly, the manufacturer of tirzepatide, has been working to solve this problem by developing a pill formulation. The prospect of oral tirzepatide tablets has generated significant interest among clinicians and patients alike, and clinical development is now well underway.

Current Clinical Trial Status

Eli Lilly is advancing oral tirzepatide through a clinical program known as SYNERGY. The SYNERGY-1 and SYNERGY-2 Phase 3 trials are evaluating the drug in adults with type 2 diabetes and obesity, respectively. Early Phase 1 and Phase 2 data confirmed that the molecule can be absorbed through the gastrointestinal tract when formulated with permeation enhancers, a technology already validated by oral semaglutide (Rybelsus). Lilly has not yet published full Phase 3 results, but the company has indicated that topline data from the pivotal obesity trial is expected in 2025, with the diabetes indication data following on a similar timeline.

The central challenge with oral GIP/GLP-1 agonists is bioavailability. Peptide molecules are degraded by stomach acid and digestive enzymes before they can reach systemic circulation. Lilly's formulation uses an absorption enhancer — sodium N-[8-(2-hydroxybenzoyl)amino]caprylate, or SNAC — to temporarily alter the local gastric environment and allow the drug to pass through the stomach lining. Patients must take the tablet on an empty stomach with a small amount of water and wait before eating, a protocol that mirrors the requirements for Rybelsus.

What the Phase 2 Data Showed

In a dose-ranging Phase 2 study, oral tirzepatide produced meaningful reductions in HbA1c and body weight across multiple dose levels. The 45 mg daily dose achieved weight loss results that were competitive with the injectable formulation in terms of the direction and magnitude of effect, though cross-trial comparisons are inherently limited. Gastrointestinal side effects — nausea, vomiting, and diarrhea — were dose-dependent and consistent with the known profile of injectable tirzepatide. Importantly, no new safety signals emerged that would be specific to the oral route. These results gave Lilly enough confidence to move directly into large Phase 3 trials.

Projected Approval and Launch Timeline

If Phase 3 trials report positive results in 2025 as anticipated, Eli Lilly could file a New Drug Application with the FDA in late 2025 or early 2026. The FDA's standard review period runs approximately ten to twelve months, which would place a potential approval in 2026 or 2027. A priority review designation, which shortens the standard timeline to six months, is possible if the agency determines the drug addresses an unmet medical need — a plausible outcome given the scale of the obesity epidemic and the current limitations of oral options.

Regulatory pathways outside the United States add additional complexity. The European Medicines Agency and Health Canada would each require separate submissions and review periods, meaning international availability would likely lag the US launch by at least one to two years. Pricing and formulary negotiations with payers will also shape how quickly patients can actually access the drug after approval.

How Oral Tirzepatide Tablets Compare to Injectable Options

The practical advantages of a pill over a weekly injection are real, but they come with trade-offs that clinicians will need to weigh carefully with each patient.

• Dosing frequency: oral tirzepatide is taken daily, while injectable tirzepatide requires only one injection per week.
• Bioavailability variability: oral absorption is more sensitive to food intake, gastric emptying rate, and adherence to fasting requirements than subcutaneous injection.
• Needle avoidance: patients with needle phobia or who struggle with injection technique may find the pill formulation more sustainable long-term.
• Storage: pills do not require refrigeration, simplifying travel and storage compared to injectable pens.

For patients who are already doing well on injectable tirzepatide, there may be little clinical reason to switch. The oral formulation is likely to serve primarily as an entry point for patients who have declined injectable therapy or who are earlier in the treatment algorithm. Clinicians will also be watching closely to see whether efficacy data from the oral Phase 3 trials matches the weight loss benchmarks set by the injectable program.

What Patients Should Know Now

As of mid-2026, oral tirzepatide tablets remain in clinical development and are not yet commercially available. Patients interested in this option should discuss the current status of the SYNERGY trials with their prescriber and monitor announcements from Eli Lilly and the FDA. In the meantime, injectable tirzepatide continues to be the approved standard of care for eligible patients with obesity or type 2 diabetes. Anyone considering tirzepatide in any form should do so only under the supervision of a licensed healthcare provider, as this remains a prescription medication with a defined safety and monitoring protocol.